Thomas Civik - 07 Oct 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: Director
Issuer ticker: PYXS
Reported as of: 07 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Oct 2021, 19:47:58 UTC
Prior SEC filing: 09 Sep 2021
Next SEC filing: 18 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Pamela Connealy, Attorney-in-Fact for Thomas Civik

Key filing fact

Thomas Civik filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 12 Oct 2021.

Key facts

This page summarizes Thomas Civik's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Oct 2021, 19:47.

Change

Previous filing in this sequence was filed on 09 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +42,191
Change %
Price: $0.000000
Shares after: 42,191
Date: 07 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,191
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.